NDAORALCAPSULE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
MONODOX (doxycycline monohydrate) by Molecular Devices is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. First approved in 1989.
Drug data last refreshed 18h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONODOX is a doxycycline monohydrate oral capsule, a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It demonstrates bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. The drug is virtually completely absorbed after oral administration with a half-life of approximately 16 hours.
LOE Approaching
This product is in late-stage lifecycle approaching loss of exclusivity, signaling defensive commercial strategies and potential team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after…
Worked on MONODOX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.